For example, VEGF inhibitors Bevacizumab, the FDA-approved antiangiogenic monoclonal antibody (mAb), capable of reverting abnormal structure of tumor vessels toward a more normal phenotype have been applied in the treatment of metastatic colorectal cancer (Salgaller, 2003; Ellis, 2005; Table 1), which were of high potential to improve nanomedicine delivery for tumor treatment. Here, VEGFA is linked to neoplasm.